Meeting
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.
Authors
Wilson H. Miller Jr.
Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada
Wilson H. Miller Jr., Tae Min Kim , Carrie B. Lee , Keith T. Flaherty , Sunil Reddy , Rahima Jamal , Laura Q. Chow , Isabelle Anne Rooney , Bethany Pitcher , Edward Cha , Jeffrey R. Infante
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT01988896
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3057)
DOI
10.1200/JCO.2017.35.15_suppl.3057
Abstract #
3057
Poster Bd #
152
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
First Author: Ryan J. Sullivan
Poster
2024 ASCO Annual Meeting
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.
First Author: Joachim Aerts
Poster
2022 ASCO Annual Meeting
Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).
First Author: Maria Cortes
Poster
2022 ASCO Gastrointestinal Cancers Symposium
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
First Author: Samuel J Klempner